Instil Bio Inc (TIL)
26.50
-2.94
(-9.99%)
USD |
NASDAQ |
Nov 15, 16:00
26.52
+0.02
(+0.08%)
After-Hours: 20:00
Instil Bio Research and Development Expense (TTM): 20.65M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 20.65M |
| March 31, 2024 | 26.19M |
| December 31, 2023 | 39.60M |
| September 30, 2023 | 58.34M |
| June 30, 2023 | 89.51M |
| March 31, 2023 | 122.55M |
| December 31, 2022 | 141.06M |
| September 30, 2022 | 162.91M |
| Date | Value |
|---|---|
| June 30, 2022 | 152.32M |
| March 31, 2022 | 132.00M |
| December 31, 2021 | 107.25M |
| September 30, 2021 | 74.92M |
| June 30, 2021 | 50.76M |
| March 31, 2021 | 31.82M |
| December 31, 2020 | 19.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
19.40M
Minimum
Dec 2020
162.91M
Maximum
Sep 2022
81.95M
Average
74.92M
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
| Merck & Co Inc | 22.98B |
| Elite Pharmaceuticals Inc | 7.903M |
| BioCardia Inc | 5.069M |
| Zevra Therapeutics Inc | 46.33M |
| NovaBay Pharmaceuticals Inc | 0.064M |